Real-Life Outcomes of Multiple Sclerosis Treatment With Rebif on Employment Status, Quality of Life and Cognition: a Pilot Study

CompletedNot a drug-phase studyRelapsing and progressiveNCT02377323

What it found

No results found

We found no results in the registry or in papers.

This trial finished 11 years ago. We found no results in the registry or in any paper that cites it.

What was tested

Treatment tested

  • MACFIMS
  • MSQoL-54

What it measured

Main measures

  • Employment status

    baseline

Other measures (2)

  • Quality of life

    Baseline

    Quality of life (reported by participants)
  • Cognitive function

    Baseline

    Thinking and memory

Who could take part

Relapsing and progressive · 18 and over

Show the full criteria

Inclusion criteria

* Patients with CIS or definite MS (RRMS or SPMS); * Patients seen at our Clinic within the last 2 years; * Patients untreated, or treated with either low dose or high dose Rebif for at least two years; * Patients between 18 to 60 years old at time of treatment initiation; * EDSS ≤ 5.5 at treatment initiation; * Patients able to read and write in French.

Exclusion criteria

* Patients diagnosed with primary progressive MS; * Patients treated with other DMD, other than Rebif; * Co-existence of other diseases that could influence outcomes.

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

The purpose of this study is to determine whether Rebif has an impact on employment status, quality of life and cognition.

Papers

Loading reviews and guidelines…

History

    1. Started

      Jan 2014

    2. Main results due

      May 2015

    3. Finished

      Dec 2016

    Assembled by software from public sources.